HIV used to cure 2 genetic diseases: The idea of an Italian scientist proves successful

(Press-News.org) The AIDS virus can be used to treat two severe hereditary diseases. After an Italian scientist's "stroke of genius" in 1996, and after years of promising results in the laboratory, double official recognition by one of the most important international scientific journals has now arrived. And six children from all over the world, after three years of treatment, are well and show significant benefits. The announcement was made in two studies published today in Science* by researchers at the San Raffaele Telethon Institute for Gene Therapy (TIGET) in Milan, led by Luigi Naldini, demonstrating that gene therapy vectors derived from the HIV virus works against two severe genetic diseases, metachromatic leukodystrophy and Wiskott-Aldrich syndrome.

"Three years after the start of the clinical trial," says Naldini, "the results obtained from the first six patients are very encouraging: the therapy is not only safe, but also effective and able to change the clinical history of these severe diseases. After 15 years of effort and our successes in the laboratory, but frustration as well, it's really exciting to be able to give a concrete solution to the first patients," explains the director of TIGET.

At the origin of both diseases is a genetic defect that results in the deficiency of a protein essential for the organism in the early years of life. In the case of metachromatic leukodystrophy, which currently lacks any effective treatment, it is the nervous system to be affected: babies with this disease are apparently healthy at birth, but at some point they begin to gradually lose the cognitive and motor skills they have acquired, with no possibility of arresting the neurodegenerative process. Children with Wiskott-Aldrich syndrome, on the other hand, have a faulty immune system that makes them much more vulnerable than normal to the development of infections, autoimmune diseases and cancer, as well as having a defect in the platelets which causes frequent bleeding.

VIDEO: This videoclip explains the mechanisms of the gene therapy used by researchers at San Raffaele Telethon Institute for Gene Therapy, in Milan.
Click here for more information.

After the positive results obtained in the course of many years of study in the laboratory, researchers at the San Raffaele Telethon Institute in Milan tried to correct the genetic defect that causes these diseases with gene therapy. The technique consists in withdrawing hematopoietic stem cells from the bone marrow of the patient and introducing a corrected copy of the gene that is defective using viral vectors derived from HIV (which began to be developed in 1996, thanks to Luigi Naldini's work). Once re-injected into the body, the treated cells are able to restore the missing protein to key organs.

"In patients with Wiskott-Aldrich syndrome, blood cells are directly affected by the disease and the corrected stem cells replace the diseased cells creating a properly functioning immune system and normal platelets. Thanks to gene therapy, the children no longer have to face severe bleeding and infection. They can run, play and go to school," explains Alessandro Aiuti, coordinator of the clinical study on these patients and Head of Research of the Pediatric Clinic at TIGET. "In the case of metachromatic leukodystrophy, however," says Alessandra Biffi, who heads the other study, "the therapeutic mechanism is more sophisticated: the corrected hematopoietic cells reach the brain through the blood and release the correct protein that is 'gathered' there by the surrounding nerve cells. The winning card was to make engineered cells able to produce a quantity of protein much higher than normal, and thus effectively counteract the neurodegenerative process." Eugenio Montini, who coordinated the molecular analysis of patients' cells, adds, "Until now we have never seen a way to engineer stem cells using gene therapy that is as effective and safe as this one. These results pave the way for new therapies for other more common diseases."

Both trials, which involved a team of over 70 people including researchers and clinicians, began in the spring of 2010, and called for the participation of 16 patients in total, 6 suffering from Wiskott-Aldrich syndrome and 10 from metachromatic leukodystrophy. The results published in Science refer only to the first 6 patients (three from each study), i.e. those for whom sufficient time has passed after administration of the therapy to allow scientists to draw the first significant conclusions regarding its safety and efficacy. In total, the Telethon Foundation has invested 19 million Euro for research on these two diseases (11 on metachromatic leukodystrophy and 8 on Wiskott-Aldrich syndrome).

"These preliminary results are promising and confirm the effectiveness of our efforts, which we have sustained over the years with great conviction," says the general manager of Telethon, Francesca Pasinelli. "We can say that we have created a model in which the charity organization acts not only as a funding agency, but plays a primary role in managing the development of research to ensure that each step of the process leads to the final objective, which is to provide accessible therapy to patients. To this end, we also chose to contribute towards the creation of a dedicated clinical unit and to select an Italian partner such as MolMed for vector development and production."

For Maria Grazia Roncarolo, scientific director of the San Raffaele Institute and the woman who designed and led the preparatory studies of the clinical trials of therapy for Wiskott-Aldrich syndrome, "the results described in these two studies make me very proud, both as scientific director and as pediatrician who has dedicated her entire professional life to children affected by genetic diseases. These goals are an example of how research conducted with accuracy, determination and total commitment can produce the desired results and lead to new frontiers in medicine. The translational path, from the bench in lab to the bedside of patients affected by Wiskott-Aldrich syndrome and metachromatic leukodystrophy, has also presented obstacles and frustrations, both for researchers and for parents and children who understandably find it hard to accept science 'slowness'. But the results we're showing today repay us of all the efforts and give us a great hope for the future of these children and for the possible cure of other genetic diseases".

"For years ago, when I was appointed president of Telethon – says Luca di Montezemolo – the two clinical trials at TIGET were about to start. It was a great scientific gamble and, overall, it represented an answer to the expectations of many families and patients. Today my first thought goes to them, to all those parents who contributed to our studies in the last years, although they knew research couldn't get there in time to save their own children. I also want to thank the scientists who achieved this extraordinary success and the million of Italians who have supported us with their donations".

Professor Gabriele Pelissero, Vice President of the San Raffaele Hospital concludes: "Once again our hospital proves to be a centre of excellence for the Italian healthcare system. We need to make these important realities grow in order to accept the challenge presented by the opening of the European healthcare boarders, so that we will be able to develop know-how, technologies and skills, to both continue treating Italian patients and attract patients from other countries as all the major European hospitals are about to do."



INFORMATION:

For more information, see also TIGET website and Telethon website